International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-1 doi: 10.5281/zenodo.10517277
Original Article
Investigation of Pulmonary Complications in Dengue Patients at a Tertiary Care Hospital
 ,
 ,
 ,
Published
Jan. 16, 2024
Abstract

Background: Dengue fever, a significant public health concern, is known for its systemic and potentially severe complications. This study aimed to investigate the incidence and nature of pulmonary complications in dengue patients.

Methods: In this prospective study, 100 patients with confirmed dengue infection were evaluated for the development of pulmonary complications. Data on demographic characteristics, clinical presentation, laboratory findings, radiological results, treatment, and outcomes were collected and analyzed.

Results: Pulmonary complications were observed in 43% of the patients. The most common complication was pleural effusion (20%), followed by pulmonary edema (10%), acute respiratory distress syndrome (ARDS) (8%), and pneumothorax (5%). The study highlighted a significant association between older age (>40 years) and increased risk of pulmonary complications (OR 2.5, p = 0.005). Patients with pulmonary complications had a longer hospital stay (mean 7 days, SD ± 2) compared to those without (mean 4 days, SD ± 1, p < 0.01) and were more likely to require ICU admission (23.25% vs. 3.51%, p < 0.001).

Conclusion: The study demonstrates a high incidence of pulmonary complications in dengue patients, with age being a significant risk factor. These findings underscore the need for vigilant monitoring and early intervention in managing dengue, particularly in older patients

Recommended Articles
Loading Image...
Volume-5, Issue-1
Citations
1037 Views
385 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved